Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. - sprookjes - yvandenbroek - TriplyDB

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

http://www.wikidata.org/entity/Q46458338

about

Follicular lymphoma: 2012 update on diagnosis and management Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma Follicular lymphoma: 2011 update on diagnosis and management Developing strategies in the immunotherapy of leukemias Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma Follicular lymphoma: 2014 update on diagnosis and management Treatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development.The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How Role of Maintenance Rituximab (Rituxan) Therapy In the Treatment of Follicular Lymphoma When to treat patients with relapsed follicular lymphoma.Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.Radioimmunotherapy with (131)I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL).Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease.Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies The clinical development of obinutuzumab for the treatment of follicular lymphoma.Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape.The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey.Active idiotypic vaccination versus control immunotherapy for follicular lymphoma Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma.Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry.Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.Evidence of B cell immune responses to acute lymphoblastic leukemia in murine allogeneic hematopoietic stem cell transplantation recipients treated with donor lymphocyte infusion and/or vaccination.Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.

P2860

Q22252956-A4FE4344-24F7-43A5-BD41-976F9A6B775B Q24599100-F788725E-7700-4F18-BF14-6626F45747E8 Q26747753-D83A2454-6811-4C97-8F9A-BD61C492BFE6 Q26775837-49F9BE96-91A0-4F74-9AAE-0D4BEE55C743 Q26851450-6B1B48B8-A674-4F8A-9D58-5BEB37BB76AC Q26996310-C8D4F1F6-E95A-4CC1-96FE-4958F8428EEA Q27000310-EB214D60-C989-4FEE-9AD3-A966F13EA1A0 Q27021850-86444B38-E069-43D5-A50E-6C861BEA3E8F Q27693252-07B89E4B-CEFE-4FBD-9279-2B1E31FE5109 Q28072397-4CFCFACC-FFA7-495D-9585-104AB50E54F5 Q28073262-84FDBBA7-EDFC-46FB-A014-FFF795B8DB2B Q28972464-03B36FCA-FE7D-41A5-9EC0-7047987D23D5 Q30238528-C2977278-BA3F-4516-8CA7-B0D27B54FE30 Q30764873-DD550B23-0746-4F24-9D42-7609BA983110 Q33383576-28C3E5CD-4F31-4FC3-9014-C50F1FAA5F11 Q33392784-4B0A156E-C81C-471A-BD09-7629397C92C0 Q33394597-DE981C60-2BE3-48FC-95F7-50B4EC075688 Q33395360-6CB16EEC-E646-44B2-AD31-E43059065F9D Q33403958-F7195291-64E7-4E0F-BCEA-65D7ABA9F8D6 Q33415880-FC547AF0-EF26-4BCD-9992-CD30945C640D Q33416533-576A8A27-070E-4B21-AEC8-F8C40773765C Q33416554-C01E280F-E67D-4121-8D6A-DA351B73B5A1 Q33418964-6EB87D4D-DA3F-4F08-BFAD-613D7BCC00B6 Q33422543-38436575-F259-47A3-882D-961CA68AA3F6 Q33565265-1B887501-7E2D-437A-8AAF-AC2EC27E3B93 Q33621041-75BFA6E1-8887-4E92-9EFA-0D98680ABCE2 Q33665611-A37E91CE-596E-42F3-B100-312D61C51E9F Q33673144-1F8B020D-E99D-4A73-8806-D8DC1CC848CC Q33691505-F4F1B0B4-DCEC-473C-AE3C-1158DF9D4F84 Q33781006-63E111A5-AE5C-4934-A2D7-14D4BA2782A7 Q33830194-0784CDBD-F2FC-4A06-88A1-9BB70F41CC57 Q34059352-69F5D998-074C-4311-B32E-F03245F8A633 Q34093532-8050E6EA-2067-4B6D-BF0B-8C710FAB9A68 Q34112470-C9DC904B-4732-4D65-A16E-A58C149C4447 Q34360360-6AF832CA-BB7A-4972-BBFD-BFE11F32FBAA Q34391446-760B5E5F-8F65-4648-9995-04624262873B Q34532716-C38299E9-6FE4-41FB-AE24-D91D2C83DC10 Q34619308-060E1097-60FB-464C-B696-0FF0A2DCD5B1 Q34623592-DD661132-497E-4D72-A305-6DF4CA45047B Q34646321-FA65CE53-2509-4AD2-9B89-2BF1C554F3A6

P2860

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

http://www.wikidata.org/entity/Q46458338

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Phase III study of R-CVP compa ...... advanced follicular lymphoma.

@en

Phase III study of R-CVP compa ...... advanced follicular lymphoma.

@nl

type

label

Phase III study of R-CVP compa ...... advanced follicular lymphoma.

@en

Phase III study of R-CVP compa ...... advanced follicular lymphoma.

@nl

prefLabel

Phase III study of R-CVP compa ...... advanced follicular lymphoma.

@en

Phase III study of R-CVP compa ...... advanced follicular lymphoma.

@nl

P1433

Q46458338-FDED9112-DCE1-4514-814A-720B17646637

P1476

Q46458338-6D08E7A6-4A46-4D4F-8F08-58CF5E047997

P2093

Q46458338-1563A4BB-0B5D-4055-846B-6B12ABF67B0F

Q46458338-1FF5B750-4C14-46B5-8B65-F3CDBD5EFAA5

Q46458338-653B17C1-6C74-415B-97B4-71CAA9F09104

Q46458338-72EBC834-E1DD-4DEC-9DA1-251ABDA8D4F6

Q46458338-93DD4B38-17C2-4828-A20F-4345117A0B80

Q46458338-98FAF1C1-D2C7-4E93-9DE2-BB1E766F34FA

Q46458338-C4CF8767-ADF9-423A-96D8-BF254E542A65

Q46458338-C68EC761-FC36-498E-BB58-15AE1A583EE5

Q46458338-CA77CF06-BFD1-4592-A8A9-575955F4C243

Q46458338-F34228E3-8573-4CB7-AC3D-D58D5D72BAE1

P304

Q46458338-6AC566A8-76C7-4803-93E8-1919F4A60941

P31

Q46458338-751B4A3D-A081-4E35-83BE-C62C2FE5BF37

P356

Q46458338-ACD83724-3B32-4D1F-B6E8-4F3CF8B11A29

P407

Q46458338-B76F0D43-32DC-4303-8370-860A47D2C332

P433

Q46458338-F42E54F2-382A-4B45-9F1C-482215A32134

P478

Q46458338-E5AE138B-1352-4A70-9392-3184ABAF89CB

P50

Q46458338-19C0CEB8-52CD-41FD-B783-B6A1D342ABC6

Q46458338-E3F1A2F3-5F34-4E6E-983A-702658186DDA

P577

Q46458338-AE1648A0-B283-45CE-8A2B-7B6931F84182

P5875

Q46458338-B195E3BE-3B92-49BD-AF33-E7F3CE210E9F

P698

Q46458338-DC3317A7-A1D6-4C56-9E2A-DFDBF3D97910

P921

Q46458338-178B7207-4A87-4FD4-B8C6-802463E68880

P356

JCO.2007.13.5376

P1433

Journal of Clinical Oncology

P1476

Phase III study of R-CVP compa ...... advanced follicular lymphoma.

@en

P2093

Andrew Belch

http://www.w3.org/2001/XMLSchema#string

Elisabeth Wassner-Fritsch

http://www.w3.org/2001/XMLSchema#string

Fritz C Offner

http://www.w3.org/2001/XMLSchema#string

George Stein

http://www.w3.org/2001/XMLSchema#string

John V Catalano

http://www.w3.org/2001/XMLSchema#string

José Gomez-Codina

http://www.w3.org/2001/XMLSchema#string

João C Raposo

http://www.w3.org/2001/XMLSchema#string

Kevin Imrie

http://www.w3.org/2001/XMLSchema#string

Philippe Solal-Celigny

http://www.w3.org/2001/XMLSchema#string

Robert Marcus

http://www.w3.org/2001/XMLSchema#string

P304

4579-4586

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.13.5376

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

David Cunningham

Anna Dmoszyńska

P577

2008-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23133575

http://www.w3.org/2001/XMLSchema#string

P698

18662969

http://www.w3.org/2001/XMLSchema#string

P921